UNSPSC 51286701: Aditoprim

This classification denotes a dihydrofolate reductase inhibitor and anti-infective agent with the molecular formula C15H21N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z81WDX2ZH, chemically known as 2,4-pyrimidinediamine, 5-((4-(dimethylamino)-3,5-dimethoxyphenyl)methyl)- but more generally known as aditoprim, which bears US NIH Compound Identifier 68755. European Medicines Agency schedules Aditoprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05275MIG.

The term ADITOPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 37, No. 6, 1983, List 23). ADITOPRIM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C1C(N(C)C)C(OC)CC(CC2C(NC(NC2)N)N)C1)C.

UNSPSC 51286701 Aditoprim is a Commodity code that does not reflect the actual pharmaceutical products and services state and local governments are currently procuring. Recent opportunities tagged under this code include antibiotic tablets (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) supplied through cooperative pharmaceutical warehousing contracts, and naloxone plus drug deactivation systems procured for community health support. The code shows little relevant recent activity aligned with its nominal scope; the two recorded opportunities involve different pharmaceutical product lines altogether, suggesting potential miscoding in the source data rather than active market demand under Aditoprim specifically.

Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (IFB process, completed award, not an open solicitation), and Seminole County, Florida released an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though the response deadline of July 26, 2023 appears to be a date error in the source. These represent the only recent state and local records under the code. Given the mismatch between the code's nominal pharmaceutical scope and the actual products being bought, pursue this code only if your firm supplies pharmaceutical products through state or cooperative purchasing vehicles; otherwise, monitor for corrected coding that better reflects current market activity.